Arcadia Biosciences(RKDA) - 2025 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q1 2025, total revenues were approximately $1,200,000, representing a 22% increase compared to the same period last year [16] - Zola revenues increased 90% year over year, driven by new distribution gains [4][17] - The cost of revenues in Q1 was approximately $680,000, a 45% increase compared to the same period last year, with a gross margin rate of 43% [17] - Selling, general and administrative costs were $1,700,000, down from $2,100,000 in Q1 2024 [19] Business Line Data and Key Metrics Changes - Zola coconut water sales increased 90% year over year, with a 70% increase in new distribution [4][5] - Sell-through data for Zola increased 76% during the thirteen weeks ended March 29, 2025, compared to a 24% growth in the coconut water category [6] - The company has successfully launched new flavors, with pineapple sales exceeding last year's total in the first four months of 2025 [7] Market Data and Key Metrics Changes - Coconut water continues to outpace the growth of many beverage categories, driven by consumer preferences for healthier options [6] - The company has replenished inventory ahead of the beverage season, mitigating potential impacts from recently announced tariffs [9] Company Strategy and Development Direction - The company is focused on expanding Zola's market presence and monetizing its intellectual property [5][10] - Arcadia is exiting its legacy ag tech business and has made significant progress in this area, including the return of certain patents [10][12] - The pending business combination with Roosevelt Resources is on track to be completed by the end of summer 2025 [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued momentum from 2024 into 2025, with strong sales growth and a healthy pipeline of opportunities [35] - The company anticipates that the impact of tariffs will be minimal due to identified cost-saving opportunities [9] - Management highlighted the importance of maintaining gross margins above 30% for nine consecutive quarters [35] Other Important Information - The company ended Q1 with $3,200,000 in cash, down from $4,200,000 at the start of the year, reflecting ongoing M&A expenses [20] - The company expects to receive approximately $2,500,000 in cash as the first repayment of principal and interest from a note receivable [21] Q&A Session Summary Question: Can you quantify any successes in expanding the Zola distribution pipeline? - Management indicated that the pipeline is about half of the current distribution, which is approximately 3,500 stores [27] Question: Will the momentum in new accounts impact 2025 financials or be more of a 2026 event? - Management expects that most awards will have an impact on 2025 [28] Question: Is there any commercial value in the remaining patent from the legacy ag biotech business? - Management noted that while there is potential commercial value, it is licensed to a third party who is two years away from commercialization [30] Question: Confirmation on the $2,500,000 initial payment for the note receivable? - Management confirmed that the payment is scheduled for receipt in Q2 [31]